120 related articles for article (PubMed ID: 22490896)
1. [Analysis of N-E cadherin switch as an independent predictive parameter of bladder cancer survival outcomes].
Cui D; Han BM; Jing YF; Xia SJ
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):380-3. PubMed ID: 22490896
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.
Muramaki M; Miyake H; Terakawa T; Kumano M; Sakai I; Fujisawa M
Urol Oncol; 2012; 30(2):161-6. PubMed ID: 20451421
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection.
Khorrami MH; Hadi M; Gharaati MR; Izadpanahi MH; Javid A; Zargham M
Urol J; 2012; 9(3):581-5. PubMed ID: 22903481
[TBL] [Abstract][Full Text] [Related]
5. Expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract is associated with disease recurrence in patients undergoing nephroureterectomy.
Muramaki M; Miyake H; Terakawa T; Kusuda Y; Fujisawa M
Urology; 2011 Dec; 78(6):1443.e7-12. PubMed ID: 21924460
[TBL] [Abstract][Full Text] [Related]
6. p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance.
Hu X; Ruan Y; Cheng F; Yu W; Zhang X; Larré S
Int J Urol; 2011 Sep; 18(9):630-7. PubMed ID: 21672035
[TBL] [Abstract][Full Text] [Related]
7. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma.
Hong RL; Pu YS; Hsieh TS; Chu JS; Lee WJ
J Urol; 1995 Jun; 153(6):2025-8. PubMed ID: 7538603
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.
Han B; Cui D; Jing Y; Hong Y; Xia S
World J Urol; 2014 Feb; 32(1):149-55. PubMed ID: 24616912
[TBL] [Abstract][Full Text] [Related]
9. Expression of classic cadherins type I in urothelial neoplastic progression.
Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
[TBL] [Abstract][Full Text] [Related]
10. [E-CD expression and its clinical significance in human bladder carcinoma].
Hao Y; Zhao C; Li X; Teng M
Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):459-61. PubMed ID: 11829888
[TBL] [Abstract][Full Text] [Related]
11. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Yamaguchi T; Muto S; Horie S; Kitamura T
Eur Urol; 2006 May; 49(5):839-45; discussion 845. PubMed ID: 16426728
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Takeuchi T; Kitamura T
Int J Urol; 2007 Sep; 14(9):789-94. PubMed ID: 17760743
[TBL] [Abstract][Full Text] [Related]
14. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
Erdemir F; Ozcan F; Kilicaslan I; Parlaktas BS; Uluocak N; Gokce O
Int Urol Nephrol; 2007; 39(4):1031-7. PubMed ID: 17340210
[TBL] [Abstract][Full Text] [Related]
16. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
17. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study.
Cai T; Piazzini M; Nesi G; Taddei I; Sardi I; Detti B; Mondaini N; Dal Canto M; Bartoletti R
Oncol Rep; 2007 Apr; 17(4):925-30. PubMed ID: 17342338
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.
Han B; Cui D; Jing Y; Hong Y; Xia S
World J Urol; 2012 Dec; 30(6):861-7. PubMed ID: 22238119
[TBL] [Abstract][Full Text] [Related]
20. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
